Dihexa vs P21
Emerging vs Emerging
avoid Both affect neuroplasticity strongly; avoid concurrent use.
Molecular Data
Dihexa P21
Weight 504.7 Da ~1,100 Da
Half-life 8-12 days Over 3 hours (mouse plasma)
Type Modified oligopeptide CNTF-derived peptide
Key Benefits
Dihexa
01 Dramatic synaptogenesis promotion
02 10 million times more potent than BDNF
03 Cognitive enhancement and memory improvement
04 Neuroprotection and potential neuroregeneration
05 Applications for Alzheimer's, TBI, age-related cognitive decline
06 Oral bioavailability
P21
01 Potent promotion of neurogenesis in the dentate gyrus
02 Increased BDNF expression
03 Reduced tau protein pathology
04 Reduced amyloid-beta plaque formation
05 Improved cognitive function and memory
06 Restored synaptic deficits in cortex and hippocampus
07 Reduced mortality rate in AD models
08 Crosses blood-brain barrier effectively
Dosing Protocols
Dihexa
8-10mg oral or 2-5mg injectable (0.5mg/kg based on research) / Once daily in the morning
Research protocol 0.5mg/kg daily Daily or 3x weekly
Standard injectable 2-5mg total 1x daily
P21
Research compound - dosing not established for humans / Daily in animal research protocols
Research protocol Variable by study Daily
Side Effects
Dihexa
Headaches (most frequent side effect)
Anxiety or overstimulation
Sleep disruption when dosed late in day
Mental clarity increase
P21
Limited data - primarily preclinical research
Generally well-tolerated in animal studies
Contraindications
Not FDA approved - research compound only
Theoretical cancer risk via c-Met activation
Cancer history (avoid due to c-Met pathway)
Pregnancy or breastfeeding
No long-term human safety data
Not approved for human use
Pregnancy or breastfeeding
Unknown safety profile in humans
Research Evidence
Dihexa P21
Status Emerging Emerging
References 3 studies 4 studies
Latest 2024 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.